Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study
Amir Bieber, Iftach Sagy, Lena Novack, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 7, pp. 1028-1035
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Correlation between COVID-19 vaccination and diabetes mellitus: A systematic review
Yanfei He, Jing Ouyang, Xiao Hu, et al.
World Journal of Diabetes (2023) Vol. 14, Iss. 6, pp. 892-918
Open Access | Times Cited: 18
Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys
Parikshit Sen, R Naveen, Nazanin Houshmand, et al.
Lara D. Veeken (2023) Vol. 62, Iss. 10, pp. 3291-3301
Open Access | Times Cited: 17
Humoral immune response to SARS-CoV-2 vaccines in patients with autoimmune rheumatic diseases
P. M. Corbalán, Rodrigo Hernán Tomas‐Grau, Mariana Pera, et al.
Archives of Medical Research (2025) Vol. 56, Iss. 3, pp. 103141-103141
Closed Access
Efficacy, Immunogenicity, and Safety of COVID-19 Vaccines in Patients with Autoimmune Diseases: A Systematic Review and Meta-Analysis
Alvina Widhani, Anshari Saifuddin Hasibuan, Retia Rismawati, et al.
Vaccines (2023) Vol. 11, Iss. 9, pp. 1456-1456
Open Access | Times Cited: 10
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases
Clodoveo Ferri, Laura Gragnani, Vincenzo Raimondo, et al.
Journal of Autoimmunity (2022) Vol. 131, pp. 102866-102866
Open Access | Times Cited: 16
Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases
Charalampos Papagoras, Nikoleta Zioga, Vasileios Papadopoulos, et al.
Clinical Rheumatology (2023) Vol. 42, Iss. 12, pp. 3375-3385
Open Access | Times Cited: 8
Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study
Warren Fong, Ting Hui Woon, Li‐Ching Chew, et al.
Advances in Rheumatology (2023) Vol. 63, Iss. 1
Open Access | Times Cited: 7
Humoral and cellular immunogenicity of COVID-19 booster dose vaccination in inflammatory arthritis patients
Jakub Wroński, Bożena Jaszczyk, Leszek Roszkowski, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 11
The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
Ka-Wa Khong, Ruiqi Zhang, Ivan Fan‐Ngai Hung
Vaccines (2022) Vol. 10, Iss. 11, pp. 1924-1924
Open Access | Times Cited: 11
Outcomes following SARS-CoV-2 infection in individuals with and without inflammatory rheumatic diseases: a Danish nationwide cohort study
Anne-Marie Svensson, Hanne‐Dorthe Emborg, Lars Erik Bartels, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 10, pp. 1359-1367
Closed Access | Times Cited: 6
Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases
Yasuhiro Kato, Takayoshi Morita, Atsushi Kumanogoh
Inflammation and Regeneration (2023) Vol. 43, Iss. 1
Open Access | Times Cited: 5
Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients
Yusuke Kashiwado, Yasutaka Kimoto, Shiro Ohshima, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 3, pp. 725-733
Closed Access | Times Cited: 5
Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses
Pankti Mehta, Armen Yuri Gasparyan, Olena Zimba, et al.
Clinical Rheumatology (2022) Vol. 41, Iss. 12, pp. 3897-3913
Open Access | Times Cited: 8
SARS-CoV-2 infection among patients with autoimmune rheumatic diseases; comparison between the Delta and Omicron waves in Israel
Amir Bieber, Shay Brikman, Lena Novack, et al.
Seminars in Arthritis and Rheumatism (2022) Vol. 58, pp. 152129-152129
Open Access | Times Cited: 8
Additional Reassuring Data for SARS-CoV-2 Vaccination in Immune-Mediated Inflammatory Diseases, but With a Catch
Alfred H.J. Kim
The Journal of Rheumatology (2024) Vol. 51, Iss. 4, pp. 332-335
Open Access | Times Cited: 1
Persistence of SARS-CoV-2 neutralizing antibodies and anti-Omicron IgG induced by BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic disease: an explanatory study in Japan
Yuta Yamaguchi, Shinichiro Nameki, Yasuhiro Kato, et al.
The Lancet Regional Health - Western Pacific (2022) Vol. 32, pp. 100661-100661
Open Access | Times Cited: 7
Safety and reported adverse effects of coronavirus disease-2019 (COVID-19) vaccines in patients with rheumatic diseases
Fatma M. Aboud, Rasha Saad Hussein, Rasha M. Hassan
The Egyptian Rheumatologist (2022) Vol. 45, Iss. 2, pp. 133-137
Open Access | Times Cited: 7
Humoral immune response against BNT162b2 mRNA COVID-19 vaccine in patients with rheumatic disease undergoing immunosuppressive therapy: A Japanese monocentric study
Koichi Sugihara, Risa Wakiya, Tomohiro Kameda, et al.
Medicine (2022) Vol. 101, Iss. 42, pp. e31288-e31288
Open Access | Times Cited: 6
Fourth dose of BNT162b2 vaccine for patients with autoimmune rheumatic diseases in a nationwide setting
Amir Bieber, Shay Brikman, Lena Novack, et al.
Lara D. Veeken (2023) Vol. 62, Iss. 10, pp. 3332-3338
Closed Access | Times Cited: 3
COVID-19 vaccine immunogenicity in 16 patients with autoimmune systemic diseases. Lack of both humoral and cellular response to booster dose and ongoing disease modifying therapies
Laura Gragnani, Marcella Visentini, Serena Lorini, et al.
Journal of Translational Autoimmunity (2022) Vol. 5, pp. 100164-100164
Open Access | Times Cited: 5
Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients
Dániel Honfi, Nikolett Gémes, Enikő Szabó, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11411-11411
Open Access | Times Cited: 5
The Kinetics of Humoral and Cellular Responses after the Booster Dose of COVID-19 Vaccine in Inflammatory Arthritis Patients
Jakub Wroński, Bożena Jaszczyk, Leszek Roszkowski, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 620-620
Open Access | Times Cited: 2
Boosting Vaccine Response in Autoimmune Rheumatic Disease Patients With Inadequate Seroconversion: An Analysis of the Immunogenicity of Vector-Based and Inactivated Vaccines
Anuroopa Vijayan, Aswathy Sukumaran, Sara R. Jones, et al.
Cureus (2024)
Open Access
COVID-19 vaccines and their impact: An overview
Ka Wa Khong, Ivan Fan‐Ngai Hung
Elsevier eBooks (2024), pp. 379-388
Closed Access
Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort
Ketty Lysie Libardi Lira Machado, Ana Paula Neves Burian, Olindo Assis Martins‐Filho, et al.
Vaccines (2024) Vol. 12, Iss. 12, pp. 1367-1367
Open Access
Page 1 - Next Page

Scroll to top